notype correlations in a genetically determined X-linked mitral valve disease due to mutations of the filamin A (FLNA) gene.
The study was carried out by two-dimensional echocardiography in a large cohort of subjects from four families harbouring three different FLNA mutations, for a total of 65 carrier vs. 97 non-carrier relatives. The disease was confined to the heart, with mostly mitral valve abnormalities and no significant extra-cardiac findings, but joint hypermobility and a narrow palate in some individuals. Thus, it is not a syndromic disease. There was a large spectrum of mitral valve abnormalities in carriers, and the penetrance was partial or complete in two-thirds of cases.
The echocardiographic phenotype consists of valvular and subvalvular apparatus abnormalities: leaflet thickening and elongation; papillary muscle anomalies, with a short distance from the tip to the mitral annulus, abnormal position, or even absence; and annular enlargement. In contrast to mitral valve prolapse, chordae are shortened in women and chordal rupture has never been observed. Lesions are less severe in women, as expected in an X-linked disease. Overall, the morphological features of FLNA mitral valve disease are in keeping with a developmental valve defect ('dysplasia'), as also supported by polyvalvular involvement. It is noteworthy that mitral valve abnormalities are similar in adult and younger patients from early childhood, clearly pointing to a congenital heart disease, as confirmed by the few, exceptional cases at foetal echocardiography examinations. These features are in agreement with findings in transgenic mice. 2 Filamin A is a protein involved in cardiac development, particularly of the cushions from which valve leaflets originate even during foetal morphogenesis, thus explaining multiple valve lesions in FLNA mutation carriers.
Unfortunately, gross pictures or detailed descriptive anatomy from valve specimens are not available in the study by Le Tourneau et al. 1 Only histology of a surgical pathology resection was provided,
showing mitral valve leaflet thickening with myxoid degeneration. To the best of our knowledge, no pathology report has been yet published on the topic. The pathological substrate accounts functionally for mitral regurgitation (more rarely stenosis) with restrictive leaflet motion during diastole. There is clear-cut evidence of a developmental abnormality, worsening with time by progressive degenerative changes. The reported phenotype mimics carcinoid-phen fen drug-induced lesions or rheumatic valve disease, a finding which is not surprising since classical congenital mitral stenosis is also grossly quite similar to acquired post-rheumatic subvalvular mitral stenosis.
Clearly the phenotype should not be confused with mitral valve prolapse (Barlow's disease), 3 in which restrictive motion of the leaflets is quite unusual, or with classical congenital mitral valve malformations (congenital stenosis, parachute, arcade, and Stone complex). FLNA mitral valve disease is a rare, new nosographic entity, both congenital and genetic, to be added in the taxonomy of heart valve diseases. Non-syndromic mitral valve prolapse, nowadays the most common form of mitral valve disease, encompasses different phenotypes from fibro-elastic deficiency to classical Barlow disease. It affects 2-3% of the population and is a major cause of valve surgery in adults and the elderly, and even carries a risk of arrhythmic complications in a subgroup of patients. 4 The condition described in this study presents unique features compared with mitral valve prolapse and, to the best of our knowledge, represents the first isolated, genetically determined, congenital malformation of the mitral valve which is X-linked and hereditary in origin.
As far as the nomenclature used in this study is concerned, the prefix 'FLNA' to mitral valve dystrophy is correct, in the absence of an eponym, since it points to the genetic aetiology. 1, [5] [6] [7] [8] The time has come for establishment of a molecular nomenclature of genetic cardiovascular diseases. 9 However, from an etymological perspective, the term 'dystrophy' would point to a genetically determined degenerative disease. In the degenerative theory, the mitral valve abnormalities should be considered to be the consequence of acquired and progressive valvular changes due to some metabolic or genetic defect. In contrast, in the disontogenetictheory mitral valve disease is considered to be the consequence of a congenital maldevelopment of the mitral valve, leading to abnormalities of the valvular and subvalvular apparatus. Thus, the disease should be regarded as a gross cardiac structural defect present at birth and listed among the congenital heart diseases. The use of the term 'dysplasia' (which means 'maldevelopment') would be more appropriate than dystrophy. It is worth remembering that it has been considered an X-linked congenital (i.e. present at birth) valve disease since the original report by Monteleone and Fagan in 1969 (Figure 1) . 10 Mechano-related stress and injury, occurring with time, account for myxoid degeneration and functional deterioration, requiring surgical repair in adults and the elderly. These age-related secondary changes of the mitral valve apparatus with progressive myxoid degeneration are similar to those also occurring in non-FLNA mitral valve prolapse, either syndromic or non-syndromic, where dysregulation of the transforming growth factor beta 1 pathway has been demonstrated to account for extracellular matrix remodelling. 11 It may be that mitral valve prolapse is the consequence of a congenital malformation of the annulus, with leaflets and chordae myxoid tissue remodelling, as well as fibrosis of the papillary muscles and mural myocardium by mechano-injury with wear and tear.
12,13
The authors should be congratulated on the novelty of the investigation by reporting the phenotypic spectrum and the natural history of this genetic disorder. However, there are still several issues to be clarified. How frequent are de novo mutations? For instance, in Xlinked Duchenne muscular dystrophy they are reported in 30% of cases.
14 This would be important information for providing correct genetic counselling. From the embryology viewpoint, the frequent association of bicuspid aortic valve (7.7% of cases) is intriguing, considering that the latter is also reported in 40-50% of patients with aortic isthmic coarctation, which is considered a neural crest, non-genetic maldevelopment. 15 Bicuspid aortic valves were frequent even in the FLNA transgenic mice. We wonder whether FLNA disease is a maldevelopment defect affecting not only the inflow but also the outflow of the heart; in other words, a genetic disease of the endocardial cushions which are present not only at the atrioventricular but also at the ventricular arterial levels in the embryo.
In clinical terms, a high lifetime risk of cardiac surgery is reported in FLNA mitral valve patients, with up to 75% of male subjects operated at 70 years of age. As far as surgical anatomy is concerned, the malformation can be managed by valve repair even in adults and the elderly, with a fair outcome. However, the unique valvular-subvalvular features and the frequent co-existence of stenosis might explain the need for valve replacement in childhood, which has never been reported in mitral valve prolapse patients. 4 In the study of Le Tourneau et al.,
1 the natural history has been evaluated in terms of overall survival and rate of cardiac surgery. Prospective data on the incidence of atrial enlargement/fibrillation, including the need for anticoagulant therapy, are warranted. Last, but not least, no data are available on the incidence of ventricular arrhythmias and the risk of sudden death which are well known complications along the natural history of classical mitral valve prolapse. 13 Electrocardiographic and Holter monitoring data would be welcome to cover the whole spectrum of clinical manifestation of FLNA mitral valve disease.
In conclusion, FLNA mitral valve disease is a separate morbid entity. It shares no features with isolated mitral valve prolapse (Barlow's disease), which is not a hereditary disease. It is a maldevelopmental abnormality and, for this reason, we believe that it should be termed FLNA mitral valve dysplasia.
Certainly, it is quite important to be aware of the existence of this congenital valve disease, for differential diagnosis with mitral valve prolapse and inherent implications for genetic screening and counselling. 
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